Patents by Inventor Meirav Pevsner-Fischer

Meirav Pevsner-Fischer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
    Patent number: 11852634
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: December 26, 2023
    Assignees: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-Eppendorf
    Inventors: Eran Ovadia, Irun R. Cohen, Johannes Herkel, Raanan Margalit, Meirav Pevsner-Fischer
  • USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME
    Publication number: 20210041455
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicants: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-Eppendorf
    Inventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
  • USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME
    Publication number: 20190204340
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 4, 2019
    Applicants: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-Eppendorf
    Inventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
  • Use of AKT phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
    Patent number: 10288622
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: May 14, 2019
    Assignees: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-Eppendorf
    Inventors: Eran Ovadia, Irun R. Cohen, Johannes Herkel, Raanan Margalit, Meirav Pevsner-Fischer
  • USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME
    Publication number: 20160033529
    Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Applicants: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
  • URINARY BIOMARKERS FOR CANCER DIAGNOSIS
    Publication number: 20140323355
    Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MOR - RESEARCH APPLICATIONS LTD.
    Inventors: Irun R. COHEN, Meirav PEVSNER-FISCHER, David MARGEL, Jack BANIEL, Ofer YOSSEPOWITCH
  • Urinary biomarkers for cancer diagnosis
    Patent number: 8748118
    Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: June 10, 2014
    Assignees: Yeda Research and Development Co. Ltd., Mor—Research Applications Ltd.
    Inventors: Irun R. Cohen, Meirav Pevsner-Fischer, David Margel, Jack Baniel, Ofer Yossepowitch
  • URINARY BIOMARKERS FOR CANCER DIAGNOSIS
    Publication number: 20120149043
    Abstract: The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (BC) and prostate cancer (CaP). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers.
    Type: Application
    Filed: August 3, 2010
    Publication date: June 14, 2012
    Applicants: MOR - RESEARCH APPLICATIONS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Irun R. Cohen, Meirav Pevsner-Fischer, David Margel, Jack Baniel, Ofer Yossepowitch